Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.
An article from
Dive Brief
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.
Published July 9, 2026
Eplontersen, from AstraZeneca and Ionis Pharmaceuticals, failed a Phase 3 study in transthyretin-mediated amyloidosis cardiomyopathy.
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained…
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive…
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen…
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key…
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today? - AstraZeneca (NYSE:AZN), Ionis Pharmaceu
AstraZeneca, Ionis report major trial failure with heart disease drug
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)
AstraZeneca sinks on unexpected heart drug trial failure
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca shares slide 9% after heart treatment disappoints in trial
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
